The trial had 106 hospitalised Covid-19 patients with signs of an acute respiratory infection. Credit: Vachagan Malkhasyan from Pixabay.

Vicore Pharma has announced positive top-line data from the Angiotensin II Type Two Receptor Agonist Covid-19 Trial (ATTRACT) study of C21 (VP01) in hospitalised Covid-19 patients.

C21 is an orally available low molecular weight angiotensin II type 2 receptor (AT2R) agonist that activates the protective arm of the renin-angiotensin system (RAS).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, double-blind and placebo-controlled trial analysed the efficacy of oral C21 compared with placebo in 106 hospitalised Covid-19 patients with signs of an acute respiratory infection but not needing mechanical ventilation.

The patients randomly received oral treatment with C21 100mg or placebo for seven days along with the physician’s choice of standard of care.

According to the results, C21 reduced the risk of needing oxygen by 40% at the end of treatment.

As predefined in the Statistical Analysis Plan, the effect was statistically significant at the 10% level.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Moreover, one patient in the C21 group required mechanical ventilation as compared to four in the placebo group.

A trend for C21 reducing mortality was observed in the trial, with one death in the treatment group versus three in the placebo group.

Vicore Pharma CEO Carl-Johan Dalsgaard said: “Given the nature and scale of this study, we are surprised to see such a clear and significant clinical benefit for C21 and given the severity and duration of the pandemic, an oral C21 formulation with an excellent safety and tolerability profile could become an important and convenient early treatment of Covid-19, fulfilling a huge medical need.

“In addition, these results bode well for our ongoing study in idiopathic pulmonary fibrosis (IPF), as well as for future studies in larger indications where activation of AT2R may have a role to play.”